Acadia Pharmaceuticals announced it has submitted to the Food and Drug Administration (FDA) a priority review of the New Drug Application (NDA) for Nuplazid (pimavanserin) for the treatment of Parkinson’s disease psychosis (PDP).
The NDA submission was based on a pivotal Phase 3 -020 Study in which Nuplazid achieved statistically significant reduction in psychosis compared to placebo in patients with PDP with no worsening of motor function. Nuplazid met all primary and secondary endpoints with statistical significance.
Nuplazid is a first-in-class selective serotonin inverse agonist (SSIA) that selectively targets 5-HT2A receptors, which enhances 5-HT2A receptor blockade without the side effects of existing antipsychotics.
For more information call (858) 558–2871 or visit Acadia-Pharm.com.